Deucravacitinib for Lupus

(POETYK SLE-1 Trial)

Recruiting at 335 trial locations

Overseen By BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Recruiting

Sponsor: Bristol-Myers Squibb

Must be taking: Immunosuppressants, Antimalarials

Must not be taking: Cytotoxic agents

Disqualifiers: Drug-induced SLE, Other autoimmune diseases, others

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is testing a new medication called deucravacitinib to see if it can help people with moderate to severe Systemic Lupus Erythematosus (SLE). The medication works by calming down the immune system and reducing inflammation. The goal is to find out if it is safe and effective for these patients.

Will I have to stop taking my current medications?

The trial requires that you stay on at least one SLE background therapy (like an immunosuppressant or antimalarial) at a stable dose for the duration of the study. If you're taking oral corticosteroids, the dose must also be stable. So, you won't have to stop your current medications if they meet these criteria.

What data supports the effectiveness of the drug Deucravacitinib for treating lupus?

A phase II trial showed that Deucravacitinib, which works by selectively inhibiting a protein called TYK2, was tested for its effectiveness and safety in patients with active systemic lupus erythematosus (SLE). ^{1 2 3 4 5}

What is known about the safety of Deucravacitinib for humans?

In a phase II trial for systemic lupus erythematosus, Deucravacitinib was evaluated for safety, but specific safety outcomes are not detailed in the provided research summary. ^{1 3 4 6 7}

What makes the drug deucravacitinib unique for treating lupus?

Deucravacitinib is unique because it is a first-in-class, oral drug that selectively inhibits tyrosine kinase 2 (TYK2), a protein involved in immune system signaling. This mechanism helps reduce inflammation by blocking specific pathways that contribute to autoimmune diseases like lupus, making it different from other treatments that may not target TYK2. ^{3 8 9 10 11}

Research Team

Bristol-Myers Squibb

Principal Investigator

Bristol-Myers Squibb

Eligibility Criteria

This trial is for adults with active moderate to severe Systemic Lupus Erythematosus (SLE) who have a certain level of disease activity. Participants must have been diagnosed at least 24 weeks prior and be on stable SLE medication. Those with lupus overlap syndromes, recent serious infections, multiple immunosuppressants, or unstable neuropsychiatric manifestations cannot join.

Inclusion Criteria

I was diagnosed with Lupus more than 24 weeks ago.

I have been on a stable dose of my lupus medication for at least 8 weeks.

Meet the European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) 2019 classification criteria for SLE

Exclusion Criteria

My lupus was caused by medication, not naturally occurring.

I have a history of immune system problems.

I have severe lupus affecting my kidneys that might need strong medication.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either deucravacitinib or placebo to evaluate effectiveness and safety in active SLE

24 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

12 weeks

Treatment Details

Interventions

• Deucravacitinib (Janus Kinase (JAK) Inhibitor)
• Placebo (Other)

Trial Overview The study tests the effectiveness and safety of Deucravacitinib versus a placebo in treating SLE. It aims to see if Deucravacitinib can help manage symptoms better than an inactive substance without any therapeutic effect.

Participant Groups

Group I: Arm 1: Deucravacitinib Experimental Treatment 1 Intervention

Group II: Arm 2: Placebo Placebo Group 1 Intervention

Deucravacitinib is already approved in Canada for the following indications:

Approved in Canada as Sotyktu for:

• Moderate to severe plaque psoriasis

Who Is Running the Clinical Trial?

Bristol-Myers Squibb

Lead Sponsor

Trials

2,731

Recruited

4,127,000+

Headquarters

New York City, USA

Known For

Oncology & Cardiovascular

Top Products

Eliquis, Opdivo, Revlimid, Orencia

Christopher Boerner

Bristol-Myers Squibb

Chief Executive Officer since 2023

PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis

Deepak L. Bhatt

Bristol-Myers Squibb

Chief Medical Officer since 2024

MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania

Findings from Research

In two phase III clinical trials involving 1684 patients with systemic lupus erythematosus (SLE), the EQ-5D-3L index score demonstrated strong discriminant validity, effectively distinguishing between the effects of belimumab and placebo, with a significant odds ratio of 1.47.

Higher EQ-5D index scores were also able to differentiate between responders and non-responders to treatment, suggesting that even scores below full health can provide meaningful insights into health-related quality of life for SLE patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Sensitivity analysis of EQ-5D-3L index scores in terms of discriminative and known-groups validity in SLE: introducing Adequate Health State. Hua, N., Gomez, A., Lindblom, J., et al.[2023]

Dapirolizumab pegol (DZP) showed improvements in clinical and immunological outcomes for patients with moderately to severely active systemic lupus erythematosus (SLE) after 24 weeks, although the primary dose-response relationship was not statistically significant.

DZP was well tolerated with low incidences of serious adverse events, suggesting it is a safe option for SLE treatment, warranting further investigation into its clinical benefits.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Furie, RA., Bruce, IN., Dörner, T., et al.[2022]

In a phase II trial involving 363 adults with active systemic lupus erythematosus (SLE), deucravacitinib significantly improved response rates compared to placebo, with 58% of patients on the 3 mg twice daily dose achieving the SLE Responder Index 4 (SRI-4) response at week 32.

The safety profile of deucravacitinib was generally acceptable, with similar rates of serious adverse events compared to placebo, although there were higher incidences of infections and skin-related issues like rash and acne in the treatment groups.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. Morand, E., Pike, M., Merrill, JT., et al.[2023]

In a study of 188 patients with active systemic lupus erythematosus (SLE) treated with belimumab over an average of 17.5 months, 77% and 68.7% achieved significant improvement in disease activity at 12 and 24 months, respectively, indicating its efficacy.

Belimumab demonstrated a low rate of severe adverse events and maintained a high drug survival rate of 86.9% at 6 months, suggesting it is a safe treatment option for SLE in clinical practice.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. Iaccarino, L., Andreoli, L., Bocci, EB., et al.[2022]

In a phase 3 study involving 516 patients with active systemic lupus erythematosus (SLE), ustekinumab did not show superior efficacy compared to placebo, with similar response rates at week 52 (44% for ustekinumab vs. 56% for placebo).

The study was discontinued due to lack of efficacy, but there were no safety concerns, and the adverse events reported were consistent with ustekinumab's known safety profile.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. van Vollenhoven, RF., Kalunian, KC., Dörner, T., et al.[2022]

In a study of 49 patients with active systemic lupus erythematosus (SLE), sirolimus treatment significantly reduced disease activity (SLEDAI-2K score decreased from 6.2 to 4.0) and allowed for a successful tapering of prednisone dosage.

Sirolimus showed promising efficacy in improving serological markers and achieving remission in various SLE manifestations, with 100% remission in arthritis and 88.8% in skin rash, although further research is needed to clarify its role in lupus nephritis.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Clinical efficacy and safety of sirolimus in systemic lupus erythematosus: a real-world study and meta-analysis. Peng, L., Wu, C., Hong, R., et al.[2022]

In a study involving 364 patients with systemic lupus erythematosus (SLE), long-term treatment with belimumab combined with standard therapy demonstrated a stable or declining incidence of adverse events over 4 years, indicating a favorable safety profile.

The most common side effects were mild, such as arthralgia and upper respiratory infections, and serious infusion reactions were rare, suggesting that belimumab can be safely administered for extended periods in SLE patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Merrill, JT., Ginzler, EM., Wallace, DJ., et al.[2013]

Deucravacitinib, a selective tyrosine kinase 2 inhibitor, was found to be safe and well tolerated in a study involving 40 healthy Chinese subjects, with no serious adverse events reported.

The drug showed rapid absorption and a dose-dependent increase in systemic exposure, indicating that it effectively reaches the bloodstream and maintains consistent pharmacokinetics across different doses.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects. Jing, S., Lin, Y., Dockens, R., et al.[2023]

In a study involving 100 healthy volunteers, deucravacitinib was found to be rapidly absorbed with a half-life of 8-15 hours, showing a favorable pharmacokinetic profile and no serious adverse events, indicating good safety.

Deucravacitinib effectively inhibited key immune pathways (IL-12/IL-23 and type I IFN) in a dose-dependent manner, suggesting its potential as a therapeutic option for various immune-mediated diseases.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

First-in-human study of deucravacitinib: A selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2. Catlett, IM., Aras, U., Hansen, L., et al.[2023]

Deucravacitinib is a first-in-class oral TYK2 inhibitor that works by stabilizing an inhibitory interaction within the TYK2 enzyme, which is important for treating various immune-mediated diseases.

It received its first approval in the USA on September 9, 2022, for adults with moderate-to-severe plaque psoriasis, and has since been approved in Japan for multiple forms of psoriasis, indicating its efficacy and safety in managing these conditions.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Deucravacitinib: First Approval. Hoy, SM.[2022]

In a phase 3 trial involving 66 Japanese patients with moderate to severe plaque psoriasis, deucravacitinib showed significantly higher efficacy compared to placebo and apremilast, with 78.1% of patients achieving a ≥75% reduction in PASI score at Week 16.

The safety profile of deucravacitinib was comparable to that of placebo and apremilast, with similar incidence rates of adverse events, and the most common side effect being nasopharyngitis.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial. Imafuku, S., Tada, Y., Hippeli, L., et al.[2023]

References

1. England pubmed.ncbi.nlm.nih.gov

Sensitivity analysis of EQ-5D-3L index scores in terms of discriminative and known-groups validity in SLE: introducing Adequate Health State. [2023]

2. England pubmed.ncbi.nlm.nih.gov

Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. [2022]

3. United States pubmed.ncbi.nlm.nih.gov

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. [2023]

4. England pubmed.ncbi.nlm.nih.gov

Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. [2022]

5. England pubmed.ncbi.nlm.nih.gov

Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. [2022]

6. England pubmed.ncbi.nlm.nih.gov

Clinical efficacy and safety of sirolimus in systemic lupus erythematosus: a real-world study and meta-analysis. [2022]

7. United States pubmed.ncbi.nlm.nih.gov

Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. [2013]

8. Switzerland pubmed.ncbi.nlm.nih.gov

Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects. [2023]

9. United States pubmed.ncbi.nlm.nih.gov

First-in-human study of deucravacitinib: A selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2. [2023]

10. New Zealand pubmed.ncbi.nlm.nih.gov

Deucravacitinib: First Approval. [2022]

11. England pubmed.ncbi.nlm.nih.gov

Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial. [2023]